3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Efficacy and Safety of QLM1016 in Schizophrenia 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film - Schizophrenia | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 402 | 2025-10-02 | 2026-10-14 |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia SEP-363856, Placebo - Schizophrenia | Phase 3 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 538 | 2025-02-28 | 2026-10-05 |
| Treating Schizophrenia by Correcting Abnormal Brain Development Tiagabine, Placebo - Schizophrenia | Phase 3 | Active not recruiting | Beth Israel Deaconess Medical Center | 36 | 2003-11-01 | 2025-01-27 |
Mental Disorders (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3)
Antipsychotic Agents (1) · SEP-363856 (1) · Tiagabine (1)
Beth Israel Deaconess Medical Center (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Qilu Pharmaceutical Co., Ltd. (1)
United States (2) · China (1) · Japan (1)